H.C. Wainwright Sticks to Their Buy Rating for Vanda (VNDA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda, with a price target of $20.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 20.5% and a 52.08% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Vanda, and Genmab.
In a report released on November 5, B. Riley Securities also initiated coverage with a Buy rating on the stock with a $11.00 price target.
Based on Vanda’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $56.26 million and a GAAP net loss of $22.59 million. In comparison, last year the company earned a revenue of $47.65 million and had a GAAP net loss of $5.32 million
Read More on VNDA:
Disclaimer & DisclosureReport an Issue
- Vanda Pharmaceuticals’ tradipitant shows positive results in nausea, vomiting
- AnaptysBio price target raised to $36 from $20 at Truist
- Pinterest downgraded, Tractor Supply upgraded: Wall Street’s top analyst calls
- Vanda Pharmaceuticals initiated with a Buy at B. Riley
- Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges
